VANCOUVER, BC, June 8, 2026 /PRNewswire/ - Luca Mining Corp. ("Luca" or the "Company") (TSXV: LUCA) (OTCQX: LUCMF) (Frankfurt: Z68) is pleased to provide an...
~ Godrej DEI Lab Launches Queer India Now!, a new anthology Under Queer Directions ~~ Introduces 'Queer India Fellowship' to Nurture Emerging Queer Leaders...
SINGAPORE, June 8, 2026 /PRNewswire/ -- Digital travel platform Agoda has recorded a rise in family accommodation searches for domestic summer travel compared to last...
New agreement with OpenAI brings additional AI agents to rental housing at scale, transforming how properties operate and how residents experience their homes
New agreement with OpenAI brings additional AI agents to rental housing at scale, transforming how properties operate and how residents experience their homes
Copenhagen, Denmark, 7 June2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association®, held in New Orleans, Louisiana from June 5-8, 2026.
Complete reimagining of the park's family area offers a brand-new experience that encourages exploration across four distinct areas with loveable Looney Tunes™ characters at its heartLooney...
Pinellas Gulf Beach vacation rental and STR investment specialist places in the top 0.3% of residential real estate professionals in Florida, based on independently verified 2025 sales data
Pinellas Gulf Beach vacation rental and STR investment specialist places in the top 0.3% of residential real estate professionals in Florida, based on independently verified 2025 sales data
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.
•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes • Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced • Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist
ST. JOHN'S, NL, June 5, 2026 /CNW/ - Aurion Resources Ltd. (TSXV: AU) (OTCQX: AIRRF) ("Aurion") is pleased to announce that, at its special meeting (the...
The article explains how property conditions, inspection services, and home size can influence home inspection costs for buyers.BOURBONNAIS, Ill., June 5, 2026 /PRNewswire/ --...